---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047146"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:16:56.568913+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Mira Pharmaceuticals appoints Matthew Pratt Whalen to board, replacing Michael Jerman

## Summary
- Michael Jerman resigned as director and Audit Committee Chair effective Nov 18, 2024, not due to any disagreement.
- Matthew Pratt Whalen appointed as director and Audit Committee Chair effective same day.
- Whalen is a CPA with over 20 years experience, currently CFO of Power Digital Marketing since May 2021.
- Whalen also serves as director on the board of Telmoir Pharmaceuticals (NASDAQ: TELO) since August 2024.

## SEC filing metadata
- accession: 0001493152-24-047146
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224047146/0001493152-24-047146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224047146/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047146
- JSON: https://secwatch.observer/filing/0001493152-24-047146.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.